Helix Acquisition Corp. II (HLXB)
NASDAQ: HLXB · Real-Time Price · USD
10.71
-0.13 (-1.20%)
May 27, 2025, 2:28 PM - Market open
4.39% (1Y)
| Market Cap | 251.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 6.01M |
| Shares Out | 23.51M |
| EPS (ttm) | 0.26 |
| PE Ratio | 42.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,352 |
| Open | 10.82 |
| Previous Close | 10.84 |
| Day's Range | 10.65 - 10.82 |
| 52-Week Range | 10.14 - 11.59 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HLXB
Helix Acquisition Corp. II focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Boston, Massachusetts. [Read more]
Industry Shell Companies
Sector Financials
IPO Date Feb 9, 2024
Country United States
Stock Exchange NASDAQ
Ticker Symbol HLXB
Financial Performance
Financial StatementsNews
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
SOUTH SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel sma...
3 months ago - Business Wire
Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Helix Acquisition Corp. II (Nasdaq: HLXB) (the “Company”) announced today that on February 13, 2024 it closed the initial public offering of 18,400,000 Class A ordinary shares...
1 year ago - Business Wire